Outgoing CEO: Perrigo Outfitted To Sail On OTC, Rx And Euro Growth

Hendrickson recounts Perrigo's strategies to right the ship after a hole in earnings opened from investing in a European consumer health business and operating API and dietary supplement divisions and as pricing pressures on generic drugs took some wind out of its revenue sails.